Company intelligence / Profile preview

Cognetivity Neurosciences

Vancouver, British Columbia, Canadapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

The ICA/CognICA™ platform has demonstrated high sensitivity for early detection of cognitive impairment and has been validated in clinical practice for monitoring patients with Alzheimer’s disease receiving therapies such as aducanumab. It enables scalable screening and longitudinal tracking of cognition using AI-powered image-based tests delivered via touchscreen devices or web platforms.

Therapeutic areas: Neurology
Modalities: Device (digital cognitive assessment tool)Artificial intelligence platformNon-pharmacological therapy (assessment/diagnostic)
Industry: Digital Health Medical Devices

Partnerships

InterSystems IRIS for Health interoperability partnershipcollaboration with Alzheimer's Society

Beyond the preview

Go deeper on Cognetivity Neurosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognetivity Neurosciences.

Explore the full profile